Aspire Private Capital’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Aspire Private Capital’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200	Closed	-$3	–	757
2024 Q1	$3	Hold	200	–	–	﹤0.01%	722
2023 Q4	$39	Hold	200	–	–	﹤0.01%	696
2023 Q3	$73	Hold	200	–	–	﹤0.01%	690
2023 Q2	$216	Hold	200	–	–	﹤0.01%	644
2023 Q1	$140	Hold	200	–	–	﹤0.01%	637
2022 Q4	$221	Hold	200	–	–	﹤0.01%	623
2022 Q3	$0	Hold	200	–	–	﹤0.01%	679
2022 Q2	$0	Buy	+200	New	+$335	﹤0.01%	653

Other funds holding BTTX

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Aspire Private Capital's BTTX Position: Q2 2024 in Review

Aspire Private Capital sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q2 2024, closing a stake of 200 shares — an estimated $3 sold.

Aspire Private Capital first reported a position in BTTX in Q2 2022 and held it in 8 quarters. The position peaked at $221 in Q4 2022. 1 fund tracked by Wall St. Rank holds BTTX as of Q2 2024.

Aspire Private Capital reported no remaining Better Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Aspire Private Capital sold 200 Better Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $3.
Aspire Private Capital first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Aspire Private Capital's Better Therapeutics, Inc. Common Stock position peaked at $221 in Q4 2022.
1 fund tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Aspire Private Capital's 13F filing for Q2 2024, filed 15 Jul 2024.